- Pharmaceutical companies
- STADA Group
STADA Group
Phone: +61 2 9452 6656
E-mail: info@stada.com.au
Web: https://www.stada.com.au/
Type | Aktiengesellschaft |
---|---|
Traded as | FWB: SAZ |
Industry | Pharmaceuticals |
Founded | Dresden, 1895 |
Headquarters | Bad Vilbel, Germany |
Key people |
|
Products | Generic and over-the-counter drugs |
Revenue | €2.33 billion (2018) |
Operating income | €378.1 million (2018) |
Net income | €306.9 million (2018) |
Total assets | €3.335 billion (end 2014) |
Total equity | €903.3 million (end 2014) |
Number of employees | 10,416 (FTE, average 2018) |
Website | www.stada.com |
At STADA, we follow our purpose of “Caring for people’s health as a trusted partner”. In pursuit of this purpose, we are committed to further accelerating the successful trajectory of our company. STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally. STADA focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Consumer Healthcare brands such as Zoflora®, Grippostad®, Snup®, Aqualor®, Vitaprost® and Nizoral® are among the top sellers in their respective product categories. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. Headquartered in Bad Vilbel, Germany, the main drivers of the success are the committed and highly-motivated 11,100 employees (as of December 31, 2019).
For detailed contact information visit location pages below.